Effectiveness of aggressive prophylatic and preemptive therapies targeted against cytomegaloviral and Epstein-Barr viral disease after human intestinal transplantation.
Farmer
D G
DG
Department of Surgery, Dumont-UCLA Transplant Center, Los Angeles, California, USA.
McDiarmid
S V
SV
Winston
D
D
Yersiz
H
H
Cortina
G
G
Dry
S
S
Maxfield
A J
AJ
Vandenbogaart
B
B
Correa
M
M
Kroeber
A
A
Geevarghese
S
S
Busuttil
R W
RW
D000998:Antiviral Agents / Q000627:therapeutic use*; D003586:Cytomegalovirus Infections / Q000517:prevention & control*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D020031:Epstein-Barr Virus Infections / Q000517:prevention & control*; D015774:Ganciclovir / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007422:Intestines / Q000637:transplantation*; D012189:Retrospective Studies; D013997:Time Factors; D014184:Transplantation, Homologous
D000998:Antiviral Agents; D015774:Ganciclovir